Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type

Nature Genetics

Volumn 46, Issue 5, 2014, Pages 438-443

  Witkowski, Leora ^a,b   Carrot Zhang, Jian ^a   Albrecht, Steffen ^c   Fahiminiya, Somayyeh ^a   Hamel, Nancy ^a,d   Tomiak, Eva ^e   Grynspan, David ^e   Saloustros, Emmanouil ^f   Nadaf, Javad ^a   Rivera, Barbara ^a   Gilpin, Catherine ^e   Castellsagué, Ester ^a   Silva Smith, Rachel ^a,b   Plourde, François ^a,b   Wu, Mona ^a   Saskin, Avi ^a   Arseneault, Madeleine ^a   Karabakhtsian, Rouzan G ^g,v   Reilly, Elizabeth A ^g   Ueland, Frederick R ^g   Margiolaki, Anna ^f   Pavlakis, Kitty ^h   Castellino, Sharon M ⁱ   Lamovec, Janez ^j   Mackay, Helen J ^k   Roth, Lawrence M ^l   Ulbright, Thomas M ^l   Bender, Tracey A ^l   Georgoulias, Vassilis ^f   Longy, Michel ^m   Berchuck, Andrew ⁿ   Tischkowitz, Marc ^o   Nagel, Inga ^p   Siebert, Reiner ^p   Stewart, Colin J R ^q   Arseneau, Jocelyne ^r   McCluggage, W Glenn ^s   Clarke, Blaise A ^t   Riazalhosseini, Yasser ^a   Hasselblatt, Martin ^u   Majewski, Jacek ^a   Foulkes, William D ^a,b,d   more..

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^g UNIVERSITY OF KENTUCKY   (United States)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j INSTITUTE OF ONCOLOGY   (Slovenia)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m INSTITUT BERGONIÉ   (France)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^o UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^p UNIVERSITY OF KIEL   (Germany)

^q UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^r ROYAL VICTORIA HOSPITAL   (Canada)

^s ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^t UNIVERSITY HEALTH NETWORK   (Canada)

^u UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^v ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; DNA;

ALLELE; ARTICLE; CELL LINE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXOME; FAMILIAL CANCER; GENE DELETION; GENETIC COUNSELING; GERMLINE MUTATION; HUMAN; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; OVARY CARCINOMA; PRIORITY JOURNAL; SMALL CELL CARCINOMA; SMALL CELL CARCINOMA OF THE OVARY HYPERCALCEMIC TYPE; SOMATIC MUTATION; WILD TYPE; ADOLESCENT; ADULT; CHILD; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN TISSUE; IMMUNOREACTIVITY; NONSENSE MEDIATED MRNA DECAY; RNA SPLICING; STOP CODON;

BASE SEQUENCE; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; DNA HELICASES; EXOME; FEMALE; GENE COMPONENTS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS;

EID: 84899644463     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2931     Document Type: Article

References (52)

1. Scully, R.E. in Atlas of Tumor Pathology (eds. Hartmann, W.H. & Cowan, W.R.) (Armed Forces Institute of Pathology, Washington, DC, 1979).
2. Eichhorn, J.H., Young, R.H. & Scully, R.E. Primary ovarian small cell carcinoma of pulmonary type. A clinicopathologic, immunohistologic, and flow cytometric analysis of 11 cases. Am. J. Surg. Pathol. 16, 926-938 (1992).
3. Clement, P.B. Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions. Mod. Pathol. 18 (suppl. 2), S113-S129 (2005).
4. McCluggage, W.G.W. Ovarian neoplasms composed of small round cells: a review. Adv. Anat. Pathol. 11, 288-296 (2004).
5. McCluggage, W.G., Oliva, E., Connolly, L.E., McBride, H.A. & Young, R.H. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int. J. Gynecol. Pathol. 23, 330-336 (2004).
6. Young, R.H., Oliva, E. & Scully, R.E. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am. J. Surg. Pathol. 18, 1102-1116 (1994).
7. Estel, R., Hackethal, A., Kalder, M. & Münstedt, K. Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature. Arch. Gynecol. Obstet. 284, 1277-1282 (2011).
8. Ulbright, T.M., Roth, L.M., Stehman, F.B., Talerman, A. & Senekjian, E.K. Poorly differentiated (small cell) carcinoma of the ovary in young women: evidence supporting a germ cell origin. Hum. Pathol. 18, 175-184 (1987).
9. Peccatori, F., Bonazzi, C., Lucchini, V., Bratina, G. & Mangioni, C. Primary ovarian small cell carcinoma: four more cases. Gynecol. Oncol. 49, 95-99 (1993).
10. Lamovec, J., Bracko, M. & Cerar, O. Familial occurrence of small-cell carcinoma of the ovary. Arch. Pathol. Lab. Med. 119, 523-527 (1995).
11. Longy, M., Toulouse, C., Mage, P., Chauvergne, J. & Trojani, M. Familial cluster of ovarian small cell carcinoma: a new mendelian entity? J. Med. Genet. 33, 333-335 (1996).
12. Distelmaier, F. et al. Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents. Cancer 107, 2298-2306 (2006).
13. Martinez-Borges, A.R. et al. Familial small cell carcinoma of the ovary. Pediatr. Blood Cancer 53, 1334-1336 (2009).
14. McDonald, J.M. et al. Small cell carcinoma of the ovary of hypercalcemic type: a case report. J. Pediatr. Surg. 47, 588-592 (2012).
15. Van Allen, E.M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109 (2014).
16. Holley, T. et al. Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS ONE 7, e50586 (2012).
17. Shain, A.H. & Pollack, J.R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8, e55119 (2013).
18. Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592-601 (2013).
19. Wilson, B.G. & Roberts, C.W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492 (2011).
20. Kosho, T. et al. Clinical correlations of mutations affecting six components of the SWI/SNF complex: detailed description of 21 patients and a review of the literature. Am. J. Med. Genet. A. 161A, 1221-1237 (2013).
21. Wong, A.K. et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 60, 6171-6177 (2000).
22. Gunduz, E. et al. Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int. J. Oncol. 26, 201-210 (2005).
23. Sun, A. et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 67, 203-213 (2007).
24. Richter, J. et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 44, 1316-1320 (2012).
25. Smith, M. et al. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics 13, 141-145 (2012).
26. Smith, M.J. et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat. Genet. 45, 295-298 (2013).
27. Hasselblatt, M. et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am. J. Surg. Pathol. 35, 933-935 (2011).
28. Schneppenheim, R. et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am. J. Hum. Genet. 86, 279-284 (2010).
29. Witkowski, L. et al. Familial rhabdoid tumour 'avant la lettre' - from pathology review to exome sequencing and back again. J. Pathol. 231, 35-43 (2013).
30. Brennan, B., Stiller, C. & Bourdeaut, F. Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncol. 14, e329-e336 (2013).
31. Pomeroy, S.L. et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442 (2002).
32. Matsubara, D. et al. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci. 104, 266-273 (2013).
33. Scully, R.E. Classification of human ovarian tumors. Environ. Health Perspect. 73, 15-25 (1987).
34. Kupryjańczyk, J. et al. Ovarian small cell carcinoma of hypercalcemic type - evidence of germline origin and SMARCA4 gene inactivation. A pilot study. Pol. J. Pathol. 64, 238-246 (2013).
35. Lee, R.S. et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983-2988 (2012).
36. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
37. Oike, T. et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 73, 5508-5518 (2013).
38. Wilson, B.G. et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol. Cell. Biol. 34, 1136-1144 (2014).
39. FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int. J. Gynaecol. Obstet. 105, 3-4 (2009).
40. Upchurch, K.S., Parker, L.M., Scully, R.E. & Krane, S.M. Differential cyclic AMP responses to calcitonin among human ovarian carcinoma cell lines: a calcitonin-responsive line derived from a rare tumor type. J. Bone Miner. Res. 1, 299-304 (1986).
41. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
42. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
43. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
44. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
45. Witkowski, L. et al. DICER1 hotspot mutations in non-epithelial gonadal tumours. Br. J. Cancer 109, 2744-2750 (2013).
46. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
47. Robinson, J.T. et al. Integrative Genomics Viewer. Nat. Biotechnol. 29, 24-26 (2011).
48. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
49. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
50. Tohda, H., Oikawa, A., Kudo, T. & Tachibana, T. A greatly simplified method of establishing B-lymphoblastoid cell lines. Cancer Res. 38, 3560-3562 (1978).
51. Gamwell, L.F. et al. Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet J. Rare Dis. 8, 33 (2013).
52. Ventura, R.A. et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J. Mol. Diagn. 8, 141-151 (2006).